NEW YORK & PETACH TIKVA, Israel-- --BrainStorm Cell Therapeutics , a leading developer of adult stem cell technologies for neurodegenerative diseases, is proud to announce that its positive Phase I/II ALS clinical trial data was selected as the opening presentation of the prestigious Israel Neurological Association's Annual Meeting, which will ... (more)
http://www.businesswire.com/news/topix/20121211005932/en
http://www.businesswire.com/news/topix/20121211005932/en
No comments:
Post a Comment